Related Experiment Videos
Insights
Chronic hepatitis B is a widespread liver infection that can lead to cirrhosis and cancer. While T-cell immunity is key for eradication, viral mutations impact pathogenesis, and current therapies offer limited control.
Area of Science:
- Hepatology and Virology
- Immunology
Context:
- Chronic hepatitis B is a major global health concern, potentially causing liver cirrhosis and cancer.
- Viral mutations significantly influence the pathogenesis of hepatitis B virus (HBV) infection.
- Effective viral eradication relies on T-cell immune responses targeting infected hepatocytes.
Purpose:
- To summarize the current understanding of chronic hepatitis B pathogenesis and treatment.
- To highlight the role of T-cell immunity and viral mutations in HBV infection.
- To review the efficacy of existing therapies for persistent hepatitis B.
Summary:
- Chronic hepatitis B is a significant worldwide viral infection with severe outcomes like liver cancer.
- T-cell immune responses are crucial for controlling HBV replication and clearing infected cells.
- Viral mutations play a key role in disease progression and treatment response.
- Current treatments, including alpha-interferon and lamivudine, control the infection in only 25-40% of patients.
Impact:
- Understanding pathogenesis aids in developing more effective antiviral strategies.
- Identifying key immune mechanisms can lead to novel immunotherapies for hepatitis B.
- Improved treatment options are needed for the large number of patients with persistent HBV infection.
Abstract:
Chronic hepatitis B remains one of the most wide-spread and serious viral infections in humans worldwide and may lead to cirrhosis and cancer of the liver. Eradication of the virus depends primarily on T-cell immune reaction aimed at lysis of the infected hepatosytes and suppression of the virus replication without cell death due to secretion of proinflammatory cytokines. Pathogenesis of the disease is markedly influenced by viral mutations. Persistent hepatitis B virus infection can be controlled in 25-40% patients by alpha-interferon and nucleoside lamivudine therapy.